Literature DB >> 15528183

Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G.

Hiroaki Takeuchi1, Sandra Kao, Eri Miyagi, Mohammad A Khan, Alicia Buckler-White, Ron Plishka, Klaus Strebel.   

Abstract

The virus infectivity factor (Vif) is a protein encoded by most primate lentiviruses. Recent evidence suggests that HIV-1 Vif reduces the intracellular levels of the host cytidine deaminase APOBEC3G (Apo3G) and inhibits its packaging into virions. These functions of Vif are thought to be species-specific. Accordingly, HIV-1 Vif can target only human Apo3G (hApo3G), whereas, African green monkey simian immunodeficiency virus (SIVagm) Vif can inhibit African green monkey but not human Apo3G. Consistent with this, we found that SIVagm Vif does not affect the stability of exogenously and endogenously expressed hApo3G and does not prevent packaging of exogenous and endogenous hApo3G into SIVagm virions. Nevertheless, SIVagm Vif supported spreading infection of SIVagm virus in the hApo3G-positive human A3.01 T cell line and rescued infectivity of viruses produced from Apo3G-expressing HeLa cells. Sequence analysis verified that SIVagm Vif inhibited the accumulation of hApo3G-induced mutations, suggesting that SIVagm Vif is indeed active in human cells. Our data suggest that SIVagm Vif can inhibit hApo3G activity without inducing its intracellular degradation or preventing its packaging into virions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528183     DOI: 10.1074/jbc.M408987200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly.

Authors:  Takanori Hori; Hiroaki Takeuchi; Hideki Saito; Ryuta Sakuma; Yoshio Inagaki; Shoji Yamaoka
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

Authors:  Yasumasa Iwatani; Hiroaki Takeuchi; Klaus Strebel; Judith G Levin
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.

Authors:  Bindong Liu; Phuong Thi Nguyen Sarkis; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymerase.

Authors:  Mary Poss; Howard A Ross; Sally L Painter; David C Holley; Julie A Terwee; Sue Vandewoude; Allen Rodrigo
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Productive replication of Vif-chimeric HIV-1 in feline cells.

Authors:  Melissa A Stern; Chunling Hu; Dyana T Saenz; Hind J Fadel; Olivia Sims; Mary Peretz; Eric M Poeschla
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

6.  The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.

Authors:  Martin Löchelt; Fabian Romen; Patrizia Bastone; Heide Muckenfuss; Nadine Kirchner; Yong-Boum Kim; Uwe Truyen; Uwe Rösler; Marion Battenberg; Ali Saib; Egbert Flory; Klaus Cichutek; Carsten Münk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

7.  Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.

Authors:  Wenyan Zhang; Michael Huang; Tao Wang; Lindi Tan; Chunjuan Tian; Xianghui Yu; Wei Kong; Xiao-Fang Yu
Journal:  Cell Microbiol       Date:  2008-04-16       Impact factor: 3.715

Review 8.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

9.  Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.

Authors:  Hiroaki Takeuchi; Alicia Buckler-White; Ritu Goila-Gaur; Eri Miyagi; Mohammad A Khan; Sandrine Opi; Sandra Kao; Elena Sokolskaja; Thomas Pertel; Jeremy Luban; Klaus Strebel
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Authors:  Sandrine Opi; Sandra Kao; Ritu Goila-Gaur; Mohammad A Khan; Eri Miyagi; Hiroaki Takeuchi; Klaus Strebel
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.